Search

This article provides information on the efficacy and safety of cemiplimab, a drug used to treat advanced cutaneous squamous cell carcinoma (CSCC). The study conducted in Spain included 83 patients who received cemiplimab treatment, with an overall response rate of 56.6% and 33.7% experiencing complete responses. The study found that the presence of distant metastasis and a higher ECOG score were associated with a worse response to treatment. The article emphasizes the need for more real-world data on cemiplimab treatment for CSCC and highlights the importance of including patients from diverse ethnic backgrounds in clinical trials. [Extracted from the article]